Trials / NCT02661711
Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
Completed Phase 2 Drug / neuroprotection
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
- Treatment
- Aflibercept
- Gene
- Not stated
- Conditions
- Macular Oedema, Retinitis Pigmentosa
- Ages
- 16 Years to no upper limit
- Enrollment
- 30 participants
- Started
- 2016-03
- Main results expected
- 2017-10
- Results posted
- Yes
- Record last updated
- 2024-05-06
What the study is testing
The purpose of this study is to assess the safety and efficacy of intravitreal injections of Aflibercept (Eylea) in treating Cystoid Macula Oedema (CMO) in patients with underlying Retinitis Pigmentosa (RP).
Where it runs
United Kingdom (1)
- Moorfields Eye Hospital, London